AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS
Details
Age
Adult
Type of Study
Treatment
Locations
Greeley Campus
Harmony Campus
Poudre Valley Hospital
Principal Investigator
Chelsea Gawryletz
Study ID
Protocol Number: 23-1968
More information available at ClinicalTrials.gov: NCT06206837
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers